

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/572,706-Conf. #4535
(Use as many sheets as necessary)				Filing Date	January 8, 2007
				First Named Inventor	Peter Hansen
				Art Unit	1625
				Examiner Name	Z. N. Davis
Sheet	1	of	2	Attorney Docket Number	15652-08500-US

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T*
		Country Code <sup>2</sup>	Number <sup>3</sup> ·Kind Code <sup>4</sup> (if known)			
	BA	WO-2003/070277-A1	08-28-2003	Shionogi & Co, Ltd.		See US2005/0101590
	BB	WO-2006/030032-A1	03-23-2006	Janssen Pharmaceutica NV and Addex Pharmaceuticals S. A.		
	BC	WO-2006/116713-A1	11-02-2006	Amgen Inc		

Examiner  
Zinna Northington Davis/ (03/22/2011)

Date \_\_\_\_\_

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant." CITE NO. These applicant(s) or which are marked with an asterisk (\*) next to the Cite No. are not supplied under 37 CFR 1.96(a)(2)(ii)(B) because that application was filed after June 30, 2003 or is a continuation or divisional of the application in the Cite No. in the CITE NO. field. If the application was filed before June 30, 2003 or is a continuation or divisional of the application in the Cite No. in the CITE NO. field, the CITE NO. is marked with an asterisk (\*). <sup>2</sup> Enter Office that issued the document, by the two-line code (WIPO STANDARD ST.1). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the two-line code. <sup>4</sup> For Japanese patent documents, draw a line through the appropriate symbols as indicated on the document under WIPO STANDARD ST.16 to indicate that the Japanese patent mark is not a placard mark. If "F" appears between the two-line code and the Japanese patent mark, draw a line through the Japanese patent mark.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/572,706-Conf. #4535
(Use as many sheets as necessary)				Filing Date	January 8, 2007
Sheet	2	of	2	First Named Inventor	Peter Hansen
				Art Unit	1625
				Examiner Name	Z. N. Davis
				Attorney Docket Number	15652-08500-US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
CA	EISTERT, B., <i>et al.</i> , "Synthese und Reaktionen substituierter Pyrrolin-2,3-dione mit Diazoalkanen," <i>Liebigs Ann. Chem.</i> (1976), pp. 1023-1030.				See Abstract
CB	WRIGHT, J.L., <i>et al.</i> , "A neutrophil elastase inhibitor reduces cigarette smoke-induced remodelling of lung vessels," <i>Eur Respir J</i> (2003), Vol. 22, pp. 77-81.				
CC	Office Action dated 04/09/08; Ser. No. 10/569,923 (Publication No. 2006/0270666).				
CD	Office Action dated 12/12/08; Ser. No. 10/569,923 (Publication No. 2006/0270666).				
CE	Restriction Requirement dated 02/28/08; Ser. No. 10/534,720 (Publication No. 2006/0035938).				
CF	Office Action dated 06/23/08; Ser. No. 10/534,720 (Publication No. 2006/0035938).				
CG	Office Action dated 01/02/09; Ser. No. 10/534,720 (Publication No. 2006/0035938).				
CH	Interview Summary dated 07/14/09; Ser. No. 10/534,720 (Publication No. 2006/0035938).				
CI	Office Action dated 09/29/08; Ser. No. 10/569,571 (Publication No. 2007/0010551).				
CJ	Office Action dated 03/16/09; Ser. No. 10/569,571 (Publication No. 2007/0010551).				
CK	Interview Summary dated 09/28/09; Ser. No. 10/569,571 (Publication No. 2007/0010551).				
CL	Restriction Requirement dated 01/21/09; Ser. No. 10/572,640 (Publication No. 2007/0043036).				
CM	Interview Summary dated 08/04/09; Ser. No. 10/572,640 (Publication No. 2007/0043036).				
CN	Restriction Requirement dated 08/25/09; Ser. No. 12/299,879 (Publication No. 2009/0131486).				
CO	Office Action dated 12/28/09; Ser. No. 12/299,879 (Publication No. 2009/0131486).				
CP	Office Action dated 06/24/10; Ser. No. 12/299,879 (Publication No. 2009/0131486).				
CQ	Notice of Allowance and Interview Summary dated 09/23/10; Ser. No. 12/299,879 (Publication No. 2009/0131486).				

Examiner Signature	/Zinna Northington Davis/ (03/22/2011)	Date Considered
--------------------	--	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.